![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Peginterferon Lambda for the Treatment of Chronic Hepatitis B (CHB): A Phase 2b Comparison With Peginterferon Alfa in Patients With HBeAg-Positive Disease (LIRA-B)
|
|
|
Reported by Jules Levin
EASL 2014 April 9-13 London, UK
Chan HLY,1 Ahn SH,2 Chang TT,3 Peng CY,4 Wong D,5 Coffin CS,6 Lim SG,7 Chen PJ,8 Janssen HLA,9 Marcellin P,10 Serfaty L,11 Zeuzem S,12 Cohen D,13 Critelli L,13 Xu D,13 Cooney E13
1Chinese University of Hong Kong, Hong Kong SAR, China; 2Yonsei University Severance Hospital, Seoul, Korea; 3National Chen Kung University Hospital, Tainan, Taiwan; 4China Medical University Hospital, Taichung, Taiwan; 5Toronto Western Hospital University Health Network, Toronto, ON, Canada; 6Liver Unit, Division of Gastroenterology and Hepatology, University of Calgary, Calgary, AB, Canada; 7National University Hospital, Singapore; 8National Taiwan University Hospital, Taipei, Taiwan; 9Erasmus Medical Center, Rotterdam, Netherlands/University Health Network, Toronto, Canada; 10Hopital Beaujon, Clichy, France; 11Hopital Saint Antoine, Paris, France; 12Johann Wolfgang Goethe University, Frankfurt, Germany; 13Bristol-Myers Squibb Research and Development, Wallingford, CT, USA
![EASL1.gif](../images/042114/042114-14/EASL1.gif)
![EASL2.gif](../images/042114/042114-14/EASL2.gif)
![EASL3.gif](../images/042114/042114-14/EASL3.gif)
![EASL4.gif](../images/042114/042114-14/EASL4.gif)
![EASL5.gif](../images/042114/042114-14/EASL5.gif)
![EASL6.gif](../images/042114/042114-14/EASL6.gif)
![EASL7.gif](../images/042114/042114-14/EASL7.gif)
![EASL8.gif](../images/042114/042114-14/EASL8.gif)
![EASL9.gif](../images/042114/042114-14/EASL9.gif)
![EASL10.gif](../images/042114/042114-14/EASL10.gif)
![EASL11.gif](../images/042114/042114-14/EASL11.gif)
![EASL12.gif](../images/042114/042114-14/EASL12.gif)
![EASL13.gif](../images/042114/042114-14/EASL13.gif)
![EASL14.gif](../images/042114/042114-14/EASL14.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|